- Home
- CXE vs ADVM Comparison
CXE vs ADVM Comparison
Compare CXE & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXE
- ADVM
- Stock Information
- Founded
- CXE 1989
- ADVM 2006
- Country
- CXE United States
- ADVM United States
- Employees
- CXE N/A
- ADVM N/A
- Industry
- CXE Investment Managers
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CXE Finance
- ADVM Health Care
- Exchange
- CXE Nasdaq
- ADVM Nasdaq
- Market Cap
- CXE N/A
- ADVM 98.0M
- IPO Year
- CXE N/A
- ADVM 2014
- Fundamental
- Price
- CXE $3.71
- ADVM $3.83
- Analyst Decision
- CXE
- ADVM Strong Buy
- Analyst Count
- CXE 0
- ADVM 6
- Target Price
- CXE N/A
- ADVM $27.83
- AVG Volume (30 Days)
- CXE 62.9K
- ADVM 140.3K
- Earning Date
- CXE 01-01-0001
- ADVM 05-08-2025
- Dividend Yield
- CXE 4.36%
- ADVM N/A
- EPS Growth
- CXE N/A
- ADVM N/A
- EPS
- CXE 0.07
- ADVM N/A
- Revenue
- CXE N/A
- ADVM $1,000,000.00
- Revenue This Year
- CXE N/A
- ADVM N/A
- Revenue Next Year
- CXE N/A
- ADVM $1,162.55
- P/E Ratio
- CXE $51.00
- ADVM N/A
- Revenue Growth
- CXE N/A
- ADVM N/A
- 52 Week Low
- CXE $2.95
- ADVM $3.52
- 52 Week High
- CXE $3.67
- ADVM $14.16
- Technical
- Relative Strength Index (RSI)
- CXE 44.68
- ADVM 37.58
- Support Level
- CXE $3.66
- ADVM $4.76
- Resistance Level
- CXE $3.72
- ADVM $5.23
- Average True Range (ATR)
- CXE 0.03
- ADVM 0.50
- MACD
- CXE -0.00
- ADVM -0.12
- Stochastic Oscillator
- CXE 44.44
- ADVM 1.30
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.